Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 410

1.

Natural killer cells license dendritic cell cross-presentation of B lymphoma cell--associated antigens.

Dao T, Gomez-Nunez M, Antczak C, Kappel B, Jaggi JS, Korontsvit T, Zakhaleva V, Scheinberg DA.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8763-72.

2.

Tumor-draining lymph nodes of primary lung cancer patients: a potent source of tumor-specific killer cells and dendritic cells.

Kimura H, Dobrenkov K, Iida T, Suzuki M, Ando S, Yamamoto N.

Anticancer Res. 2005 Jan-Feb;25(1A):85-94.

3.

Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens.

Tosi D, Valenti R, Cova A, Sovena G, Huber V, Pilla L, Arienti F, Belardelli F, Parmiani G, Rivoltini L.

J Immunol. 2004 May 1;172(9):5363-70.

4.

DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction.

Adam C, King S, Allgeier T, Braumüller H, Lüking C, Mysliwietz J, Kriegeskorte A, Busch DH, Röcken M, Mocikat R.

Blood. 2005 Jul 1;106(1):338-44. Epub 2005 Mar 15.

5.

Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells.

Schnurr M, Scholz C, Rothenfusser S, Galambos P, Dauer M, Röbe J, Endres S, Eigler A.

Cancer Res. 2002 Apr 15;62(8):2347-52.

7.

Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.

Koido S, Hara E, Homma S, Torii A, Toyama Y, Kawahara H, Watanabe M, Yanaga K, Fujise K, Tajiri H, Gong J, Toda G.

Clin Cancer Res. 2005 Nov 1;11(21):7891-900.

8.

CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells.

Selenko N, Maidic O, Draxier S, Berer A, Jäger U, Knapp W, Stöckl J.

Leukemia. 2001 Oct;15(10):1619-26.

PMID:
11587221
9.

Molecular and cellular requirements for enhanced antigen cross-presentation to CD8 cytotoxic T lymphocytes.

Oizumi S, Strbo N, Pahwa S, Deyev V, Podack ER.

J Immunol. 2007 Aug 15;179(4):2310-7.

10.
11.

Contribution of dendritic cells' FcgammaRI and FcgammaRIII to cross-presentation of tumor cells opsonized with the anti-MHC class I monoclonal antibodies.

Signorino E, Brusa D, Granata R, Malavasi F, Ferrone S, Matera L.

Cancer Biol Ther. 2007 Dec;6(12):1932-7. Epub 2007 Sep 3.

PMID:
18087220
12.

Drug- and cell-mediated antitumor cytotoxicities modulate cross-presentation of tumor antigens by myeloid dendritic cells.

Galetto A, Buttiglieri S, Forno S, Moro F, Mussa A, Matera L.

Anticancer Drugs. 2003 Nov;14(10):833-43.

PMID:
14597879
14.

Tumor associated antigen and interleukin-12 mRNA transfected dendritic cells enhance effector function of natural killer cells and antigen specific T-cells.

Bontkes HJ, Kramer D, Ruizendaal JJ, Meijer CJ, Hooijberg E.

Clin Immunol. 2008 Jun;127(3):375-84. doi: 10.1016/j.clim.2008.02.001. Epub 2008 Mar 21.

PMID:
18358784
15.

Increased expression of HSP70 by colon cancer cells is not always associated with access to the dendritic cell cross-presentation pathway.

Matera L, Forno S, Galetto A, Moro F, Garetto S, Mussa A.

Cell Mol Biol Lett. 2007;12(2):268-79. Epub 2007 Jan 19.

PMID:
17235439
16.

Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens.

Bleifuss E, Bendz H, Sirch B, Thompson S, Brandl A, Milani V, Graner MW, Drexler I, Kuppner M, Katsanis E, Noessner E, Issels RD.

Int J Hyperthermia. 2008 Dec;24(8):623-37. doi: 10.1080/02656730802213384.

PMID:
18608582
17.

Fucoidin enhances dendritic cell-mediated T-cell cytotoxicity against NY-ESO-1 expressing human cancer cells.

Hu Y, Cheng SC, Chan KT, Ke Y, Xue B, Sin FW, Zeng C, Xie Y.

Biochem Biophys Res Commun. 2010 Feb 12;392(3):329-34. doi: 10.1016/j.bbrc.2010.01.018. Epub 2010 Jan 11.

PMID:
20067767
18.

Dendritic cells engineered to express defined allo-HLA peptide complexes induce antigen-specific cytotoxic T cells efficiently killing tumour cells.

Stronen E, Abrahamsen IW, Gaudernack G, Wälchli S, Munthe E, Buus S, Johansen FE, Lund-Johansen F, Olweus J.

Scand J Immunol. 2009 Apr;69(4):319-28. doi: 10.1111/j.1365-3083.2008.02223.x.

19.

Whole-tumor-antigen-pulsed dendritic cells elicit cytotoxic T-cell response against pediatric nasopharyngeal carcinoma in vitro.

Yufeng D, Guocheng Z, Dongliang X, Rong F, Yuhong C, Ruying L, Jingshi Z, Xuhong Z.

Med Oncol. 2009;26(1):78-85. doi: 10.1007/s12032-008-9093-8. Epub 2008 Sep 20.

PMID:
18810669
20.

[Human/mouse chimeric anti-CD20 monoclonal antibody enhances antigen presentation in dendritic cells and induces anti-lymphoma CTL effects].

Ai LM, Ren HY, Shi YJ.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Dec;15(6):1247-52. Chinese.

PMID:
18088477
Items per page

Supplemental Content

Write to the Help Desk